Retatrutide Peptides
UK research guide covering how retatrutide works, clinical evidence, potential benefits, side effects and availability.
Retatrutide peptides are investigational compounds being studied for obesity and metabolic conditions. Developed by Eli Lilly, retatrutide targets three hormone receptors involved in appetite, glucose regulation and energy metabolism.
What Are Retatrutide Peptides?
Retatrutide (LY3437943) is a triple-receptor agonist targeting GLP-1, GIP and glucagon receptors. Researchers are investigating its effects on appetite, body weight and metabolic health.
For a detailed explanation, read what is retatrutide and how it works.

Retatrutide Peptide Benefits Under Investigation
Clinical research is examining several potential effects:
- Reduced appetite and increased satiety.
- Substantial body-weight reduction in clinical trials.
- Changes in blood glucose regulation.
- Improvements in selected metabolic risk markers.
These findings concern controlled clinical studies, not independently marketed peptide products.

Retatrutide Peptides: Clinical Trial Results
In the published Phase 2 study, participants in the 12 mg group experienced an average 24.2% weight reduction after 48 weeks.
Eli Lilly subsequently reported an average 28.3% reduction over 80 weeks in the 12 mg group of its Phase 3 TRIUMPH-1 trial.
Sources: New England Journal of Medicine and Eli Lilly TRIUMPH-1 findings.

Retatrutide Peptide vs Tirzepatide and Ozempic
| Feature | Retatrutide | Tirzepatide | Ozempic |
|---|---|---|---|
| Receptors | GLP-1, GIP, glucagon | GLP-1, GIP | GLP-1 |
| Classification | Triple agonist | Dual agonist | Single agonist |
| UK status | Investigational | Authorised medicine | Authorised medicine |
| Research focus | Obesity and metabolism | Diabetes and weight management | Type 2 diabetes |
Differences in receptor activity do not establish clinical superiority without direct comparative evidence.
Retatrutide Peptide Side Effects and Safety
Commonly reported adverse effects include nausea, diarrhoea, vomiting and constipation. Heart-rate increases have also been observed in research.
Side effects may be more noticeable during dose escalation, but their duration varies. Persistent or severe symptoms require medical assessment.
Learn more in our retatrutide weight loss injections guide.

Retatrutide Peptide Pens and Research Products
Searches for retatrutide peptide 20 mg, 40 mg pens, price and monthly costs often refer to commercial research listings rather than approved medicines. A product’s stated strength is not an established human dose.
Retatrutide Peptides UK: Frequently Asked Questions
1. How long do reta side effects last?
Some gastrointestinal effects improve as treatment continues, but duration varies. Severe or persistent symptoms need medical attention.
2. Does Eli Lilly offer early access to retatrutide?
Retatrutide remains investigational. Any access outside standard trials depends on Lilly’s current programmes and applicable eligibility requirements; public access should not be assumed.
3. What are the potential side effects of taking retatrutide?
Nausea, diarrhoea, constipation and vomiting are frequently reported. Changes in heart rate have also been observed.
4. Are there ongoing retatrutide clinical trials in the UK?
Retatrutide has an international clinical development programme. UK site participation and recruitment status must be checked against current trial listings.
5. Is retatrutide available to buy in the UK?
Retatrutide is not authorised as a UK prescription medicine. Commercial research listings do not represent approved treatments for human use.
6. What does the peptide retatrutide do for you?
In clinical studies, retatrutide influences appetite and metabolic signalling through three hormone receptors. Researchers have observed substantial average weight reductions.
7. Is reta peptide like Ozempic?
Both act on GLP-1 receptors, but retatrutide also targets GIP and glucagon receptors. Ozempic contains semaglutide and is an authorised medicine.
8. How can I obtain retatrutide, and is there a dosage calculator?
Legitimate clinical access is through eligible research programmes. There is no approved UK retatrutide dosing chart or validated consumer dosage calculator. Online dosing advice, including Reddit discussions, should not be treated as medical guidance.
Research sources: New England Journal of Medicine (2023); Eli Lilly TRIUMPH-1 (2026). Last reviewed: November 2026.



